Growth Hormone Deficiency in Childhood

Funded by: Sandoz

This RCGP accredited resource of 10 assessment questions is designed to test your knowledge on diagnosing and managing growth hormone deficiency.

Successful completion of the resource provides 1 hour of CPD delivered by Learna Ltd.

Introduction

Growth Hormone (somatropin) treatment in children is indicated for a number of conditions presenting with short stature. Growth hormone (GH) is essential for normal growth in children and the main purpose of prescribing GH in childhood is to promote linear bone growth and improve final height. The prevalence of growth hormone deficiency in children is estimated to be between 1 in 3500 and 1 in 4000 children, occurring either in isolation or in combination with several other pituitary hormone deficits.

Current NICE guidelines identify other conditions for which GH treatment is licensed in childhood including chromosomal disorders and chronic renal failure and children born small for gestational age.

The diagnosis and treatment of growth disorders in childhood should always be managed within a specialist setting by paediatric endocrinologists and specialist nurses, although once stabilised on therapy shared care within the primary care setting can be arranged.

This resource of 10 assessment questions is designed to test your knowledge on diagnosing and managing growth hormone deficiency. The questions are specifically designed to test the knowledge of a healthcare professional interested in paediatric growth disorders. As such, the resource covers the main areas of treating patients according to NICE guidelines.

Aims and Objectives

On completion of this resource you should:

  • Have an improved understanding of the diagnostic criteria for growth hormone deficiency in children and adolescents.
  • Have an understanding of the stages of normal growth and pubertal development in children.
  • Have an improved understanding of the management of growth hormone treatment in children and adolescents.

Reading List:

  1. NICE: Human growth hormone (somatropin) for the treatment of growth failure in children
  2. http://jcem.endojournals.org/content/85/11/3990.full
  3. http://www.eurospe.org/clinical/clinical_publications.html
  4. http://www.bsped.org.uk